Search
Lymphoma Clinical Trials in Pittsburgh, PA
A listing of 40 Lymphoma clinical trials in Pittsburgh, PA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
37 - 40 of 40
The city of Pittsburgh, Pennsylvania, currently has 40 active clinical trials seeking participants for Lymphoma research studies.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Sign up for a clinical trial today and contribute to the advancement of medical research, paving the way for innovative treatments. Receive financial compensation for your participation and benefit from complimentary medical care.
First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
Recruiting
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: UPMC CancerCenter, Pittsburgh, Pennsylvania
Conditions: Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder)
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Gender:
All
Ages:
All
Trial Updated:
07/17/2023
Locations: University of Pittsburg, Pittsburgh, Pennsylvania
Conditions: Mycosis Fungoides, Non-Hodgkin's Lymphoma
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Recruiting
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone m... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/21/2023
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: CD20 Positive, Mantle Cell Lymphoma
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Allegheny Health Network (AHN) West Penn Hospital, Pittsburgh, Pennsylvania
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
37 - 40 of 40